BioMarin Pharmaceuticals
BMRN
411 hedge funds and large institutions have $16.3B invested in BioMarin Pharmaceuticals in 2017 Q3 according to their latest regulatory filings, with 40 funds opening new positions, 158 increasing their positions, 148 reducing their positions, and 48 closing their positions.
23% more call options, than puts
Call options by funds: $97.7M | Put options by funds: $79.3M
1.46% more ownership
Funds ownership: 98.26% → 99.72% (+1.5%)
7% more repeat investments, than reductions
Existing positions increased: 158 | Existing positions reduced: 148
4% more capital invested
Capital invested by funds: $15.6B → $16.3B (+$697M)
4% less funds holding
Funds holding: 426 → 411 (-15)
17% less first-time investments, than exits
New positions opened: 40 | Existing positions closed: 48
36% less funds holding in top 10
Funds holding in top 10: 14 → 9 (-5)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital Research Global Investors
Los Angeles,
California
|
+$172M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$124M |
| 3 |
WRF
Waddell & Reed Financial
Overland Park,
Kansas
|
+$110M |
| 4 |
Capital World Investors
Los Angeles,
California
|
+$71.9M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
+$71.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$113M |
| 2 |
Jennison Associates
New York
|
-$82M |
| 3 |
Wells Fargo
San Francisco,
California
|
-$77.9M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
-$61.1M |
| 5 |
YCMGA
York Capital Management Global Advisors
New York
|
-$54.6M |
BMRN Hedge Fund Activity: Q3 2017 in Review
411 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in BioMarin Pharmaceuticals (BMRN) for Q3 2017, worth a combined $16.3B — up 4.5% from $15.6B a quarter earlier.
Sellers outnumbered buyers: 48 funds closed out of BMRN and 40 opened new positions — a net loss of 8 holders — while 148 trimmed existing stakes and 158 added.
The largest buyer was Capital Research Global Investors, adding an estimated $172M. The largest seller was Fidelity Investments, cutting an estimated $113M.
- 411 institutional investors held BioMarin Pharmaceuticals (BMRN) as of Q3 2017, down from 426 in Q2 2017.
- Funds reported $16.3B of BioMarin Pharmaceuticals stock for Q3 2017, up 4.5% quarter-over-quarter.
- 40 funds opened new BioMarin Pharmaceuticals positions in Q3 2017 and 48 closed out, a net change of -8 holders.
- The largest BioMarin Pharmaceuticals buyer in Q3 2017 was Capital Research Global Investors, an estimated $172M added.
- The largest BioMarin Pharmaceuticals seller in Q3 2017 was Fidelity Investments, an estimated $113M sold.
Based on aggregated 13F filings for Q3 2017.